Companies Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals (ENTA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Enanta Pharmaceuticals Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers25th pct.Of 12 peer CEOs
CEO pay, last three years
- $7,856,698FY2023
- $2,695,276FY2024
- $2,769,548FY2025
CEO total pay was $2,769,548 in fiscal 2025, up from $2,695,276 in fiscal 2024.
FY2025: salary $803,300 · bonus $0 · stock awards $128,550 · option awards $1,223,975
Executives and directors
Jay Luly · CEOScott Rottinghaus · Chief Medical OfficerYat Sun Or · Chief Scientific OfficerBruce L.A. Carter, Ph.D · Chair of the BoardKristine Peterson · Independent DirectorLesley Russell, MBChB, MRCP · Independent DirectorMark G. Foletta · Independent DirectorTerry C. Vance · Independent DirectorYujiro Hata · Independent Director
Frequently asked questions
Who was the highest-paid executive at Enanta Pharmaceuticals Inc in fiscal 2025?
As disclosed, Jay Luly (President and Chief Executive Officer) was the highest-paid executive at Enanta Pharmaceuticals Inc in fiscal 2025, with total compensation of $2,769,548.
How does Enanta Pharmaceuticals Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Jay Luly's total compensation ranked at the 25th percentile of Enanta Pharmaceuticals Inc's disclosed peer group.
How did shareholders vote on Enanta Pharmaceuticals Inc's executive compensation?
As disclosed, 97.22% of shareholders supported Enanta Pharmaceuticals Inc's executive compensation in the latest say-on-pay vote.
How much does Enanta Pharmaceuticals Inc spend in total on board compensation for fiscal 2025?
As disclosed, Enanta Pharmaceuticals Inc reported total board compensation of $447,500 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jay Luly | $803,300 | $0 | $128,550 | $1,223,975 | $591,665 | $0 | $22,058 | $2,769,548 |
| President and Chief Executive Officer | ||||||||
| Scott Rottinghaus | 560,300 | 0 | 53,563 | 425,943 | 281,348 | 0 | 22,058 | 1,343,212 |
| Chief Medical Officer | ||||||||
| Yat Sun Or | 553,150 | 0 | 53,563 | 425,943 | 239,374 | 0 | 21,761 | 1,293,790 |
| Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jay Luly | $2,769,548 | $2,695,276 | $7,856,698 | ↑ +74,272 |
| Scott Rottinghaus | 1,343,212 | 1,257,074 | 1,654,724 | ↑ +86,138 |
| Yat Sun Or | 1,293,790 | 1,222,705 | 2,469,600 | ↑ +71,085 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation program is intended to align the interests of our executive officers with those of our stockholders by measuring and rewarding their performance against our research and development objectives. Consistent with this pay-for-performance philosophy, our Compensation Committee has structured certain elements of the compensation program for our executive officers, including our NEOs, to reward performance by emphasizing equity compensation opportunities, as well as variable cash incentives that are based on corporate performance measured against annual objectives that are pre-established by our Compensation Committee.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Scott Rottinghaus | OPTION | — | — | — | — | — | $425,943 |
| Jay Luly | OPTION | — | — | — | — | — | 1,223,975 |
| Jay Luly | PSU | — | — | — | — | — | 128,550 |
| Yat Sun Or | PSU | — | — | — | — | — | 53,563 |
| Scott Rottinghaus | PSU | — | — | — | — | — | 53,563 |
| Yat Sun Or | OPTION | — | — | — | — | — | 425,943 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Scott Rottinghaus | $0 | $53,563 | $425,943 | 11.2% |
| Jay Luly | 0 | 128,550 | 1,223,975 | 9.5% |
| Yat Sun Or | 0 | 53,563 | 425,943 | 11.2% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Yat Sun Or | RSU | 1,700 | — | $20,349 |
| Yat Sun Or | Option | 1,775 | 75.33 | — |
| Scott Rottinghaus | RSU | 3,500 | — | 41,895 |
| Scott Rottinghaus | Option | 4,688 | 45 | — |
| Scott Rottinghaus | RSU | 5,000 | — | 59,850 |
| Scott Rottinghaus | PSU | 5,500 | — | 65,835 |
| Yat Sun Or | PSU | 5,500 | — | 65,835 |
| Scott Rottinghaus | PSU | 6,250 | — | 74,813 |
| Yat Sun Or | PSU | 6,250 | — | 74,813 |
| Jay Luly | RSU | 6,425 | — | 76,907 |
| Jay Luly | Option | 6,738 | 75.33 | — |
| Yat Sun Or | RSU | 10,500 | — | 125,685 |
| Yat Sun Or | Option | 14,063 | 45 | — |
| Jay Luly | PSU | 15,000 | — | 179,550 |
| Jay Luly | PSU | 16,000 | — | 191,520 |
| Scott Rottinghaus | Option | 18,750 | 71.27 | — |
| Jay Luly | RSU | 31,500 | — | 377,055 |
| Jay Luly | Option | 41,875 | 45 | — |
| Scott Rottinghaus | Option | 48,375 | 8.99 | — |
| Yat Sun Or | Option | 48,375 | 8.99 | — |
| Scott Rottinghaus | Option | 70,688 | 8.83 | — |
| Yat Sun Or | Option | 70,688 | 8.83 | — |
| Jay Luly | Option | 148,500 | 8.99 | — |
| Jay Luly | Option | 203,125 | 8.83 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Bruce L.A. Carter, Ph.DIndependent · Board Chair · Compensation · Nominating and Corporate Governance | $97,500 | $0 | $61,332 | $0 | $0 | $158,832 |
| Terry C. VanceIndependent · Audit · Compensation · Nominating and Corporate Governance (Chair) | 77,500 | 0 | 61,332 | 0 | 0 | 138,832 |
| Mark G. FolettaIndependent · Audit (Chair) · Nominating and Corporate Governance | 75,000 | 0 | 61,332 | 0 | 0 | 136,332 |
| Kristine PetersonIndependent · Compensation (Chair) · Nominating and Corporate Governance | 70,000 | 0 | 61,332 | 0 | 0 | 131,332 |
| Lesley Russell, MBChB, MRCPIndependent · Audit · Nominating and Corporate Governance | 65,000 | 0 | 61,332 | 0 | 0 | 126,332 |
| Yujiro HataIndependent · Compensation · Nominating and Corporate Governance | 62,500 | 0 | 61,332 | 0 | 0 | 123,832 |
| Jay R. Luly, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $61,332 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $447,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $447,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Enanta Pharmaceuticals as a peer
Companies that benchmark against ENTA
7 companies name ENTA as a compensation peer
The list of companies that name ENTA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ARCT Arcturus TherapeuticsINO Inovio PharmaceuticalsSAGE Sage TherapeuticsVNDA Vanda PharmaceuticalsKPTI Karyopharm TherapeuticsRIGL Rigel PharmaceuticalsTVTX Travere TherapeuticsNKTR Nektar TherapeuticsALLO Allogene TherapeuticsHRTX Heron TherapeuticsALT AltimmuneLXRX Lexicon Pharmaceuticals
Peer reciprocity
The companies Enanta Pharmaceuticals Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Travere Therapeutics | 2025 | Eric Dube | $854,250 | $3,314,520 | $3,309,384 | $964,125 | $8,457,151 |
| 2 | Altimmune | 2025 | Vipin Garg | 658,694 | 1,153,600 | 4,812,167 | 357,753 | 8,026,590 |
| 3 | Sage Therapeutics | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 4 | Nektar Therapeutics | 2025 | Howard Robin | 1,106,282 | 942,081 | 2,986,535 | 1,106,282 | 6,256,954 |
| 5 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 6 | Rigel Pharmaceuticals | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 7 | Vanda Pharmaceuticals | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 8 | Lexicon Pharmaceuticals | 2025 | Michael Exton | 650,576 | 1,049,304 | 1,355,231 | 0 | 3,553,953 |
| 9 | Heron Therapeutics | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 10 | Enanta Pharmaceuticals Inc | 2025 | Jay Luly | 803,300 | 128,550 | 1,223,975 | 591,665 | 2,769,548 |
| 11 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 12 | Arcturus Therapeutics | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
| 13 | Inovio Pharmaceuticals | 2025 | Jacqueline Shea | 728,000 | 346,101 | 351,955 | 144,144 | 1,587,155 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Enanta Pharmaceuticals Inc | not disclosed | Options 80 · PSU 10 · MSU 10 | No | Alpine Rewards LLC |
| Allogene Therapeutics | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Altimmune | not disclosed | not disclosed | not disclosed | not disclosed |
| Arcturus Therapeutics | not disclosed | Options 100 | not disclosed | not disclosed |
| Heron Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Inovio Pharmaceuticals | 33% | not disclosed | Yes — Relative TSR | Aon (Human Capital Solutions practice) |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| Lexicon Pharmaceuticals | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Nektar Therapeutics | 100% | not disclosed | No | Aon |
| Rigel Pharmaceuticals | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Sage Therapeutics | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Travere Therapeutics | 150% | not disclosed | No | Aon |
| Vanda Pharmaceuticals | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-03-11 | 24,228,898 | 692,079 | 2,363 | 97.22% | Passed |
| 2025 | 2025-03-13 | 14,516,861 | 1,039,888 | 2,126 | 93.32% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-03-11 | 97.22%a |
| 2025 | 2025-03-13 | 93.32%b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be treated as votes cast for the purpose of determining the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes have no effect and will not be counted towards the vote total for any proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Brendan Luu | Chief Business Officer | 2026-02-12 | D | 3,257 | $14 | $46,412 | Common | Form 4 ↗ |
| Jay Luly | Director | 2026-02-12 | D | 6,155 | 14 | 87,709 | Common | Form 4 ↗ |
| Jay Luly | Director | 2026-02-12 | A | 15,200 | 0 | 0 | Common | Form 4 ↗ |
| Jay Luly | Director | 2026-02-12 | A | 4,800 | 0 | 0 | Common | Form 4 ↗ |
| Yat Sun Or | Chief Scientific Officer | 2026-02-12 | D | 3,413 | 14 | 48,635 | Common | Form 4 ↗ |
| Yat Sun Or | Chief Scientific Officer | 2026-02-12 | A | 5,225 | 0 | 0 | Common | Form 4 ↗ |
| Yat Sun Or | Chief Scientific Officer | 2026-02-12 | A | 1,650 | 0 | 0 | Common | Form 4 ↗ |
| Scott Rottinghaus | Chief Medical Officer | 2026-02-12 | D | 3,413 | 14 | 48,635 | Common | Form 4 ↗ |
| Scott Rottinghaus | Chief Medical Officer | 2026-02-12 | A | 5,225 | 0 | 0 | Common | Form 4 ↗ |
| Scott Rottinghaus | Chief Medical Officer | 2026-02-12 | A | 1,650 | 0 | 0 | Common | Form 4 ↗ |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 2026-02-12 | A | 4,987 | 0 | 0 | Common | Form 4 ↗ |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 2026-02-12 | D | 3,257 | 14 | 46,412 | Common | Form 4 ↗ |
| Brendan Luu | Chief Business Officer | 2026-02-12 | A | 4,987 | 0 | 0 | Common | Form 4 ↗ |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 2026-02-12 | A | 1,575 | 0 | 0 | Common | Form 4 ↗ |
| Brendan Luu | Chief Business Officer | 2026-02-12 | A | 1,575 | 0 | 0 | Common | Form 4 ↗ |
| Matthew Paul Kowalsky | Chief Legal Officer | 2026-02-12 | D | 1,902 | 14 | 27,104 | Common | Form 4 ↗ |
| Matthew Paul Kowalsky | Chief Legal Officer | 2026-02-12 | A | 4,175 | 0 | 0 | Common | Form 4 ↗ |
| Matthew Paul Kowalsky | Chief Legal Officer | 2026-02-12 | A | 1,318 | 0 | 0 | Common | Form 4 ↗ |
| CARTER BRUCE L A | Director | 2026-03-11 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark G. Foletta | Director | 2026-03-11 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yujiro Hata | Director | 2026-03-11 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristine Peterson | Director | 2026-03-11 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lesley Russell | Director | 2026-03-11 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Terry C. Vance | Director | 2026-03-11 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Rottinghaus | Chief Medical Officer | 2026-08-08 | D | 1,467 | 13 | 19,570 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (61 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jay Luly. DEF 14A, filed 2026-01-26. Section “Summary Compensation Table” · page 44. As printed: 2,769,548. View filing ↗
- Section 01, Scott Rottinghaus. DEF 14A, filed 2026-01-26. Section “Summary Compensation Table” · page 44. As printed: 1,343,212. View filing ↗
- Section 01, Yat Sun Or. DEF 14A, filed 2026-01-26. Section “Summary Compensation Table” · page 44. As printed: 1,293,790. View filing ↗
- Section 03, Scott Rottinghaus OPTION. DEF 14A, filed 2026-01-26. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jay Luly OPTION. DEF 14A, filed 2026-01-26. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jay Luly PSU. DEF 14A, filed 2026-01-26. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Yat Sun Or PSU. DEF 14A, filed 2026-01-26. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Rottinghaus PSU. DEF 14A, filed 2026-01-26. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Yat Sun Or OPTION. DEF 14A, filed 2026-01-26. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2025-11-19. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Bruce L.A. Carter, Ph.D. DEF 14A, filed 2026-01-26. Section “Director Compensation”. As printed: 158,832. View filing ↗
- Section 08, Terry C. Vance. DEF 14A, filed 2026-01-26. Section “Director Compensation”. As printed: 138,832. View filing ↗
- Section 08, Mark G. Foletta. DEF 14A, filed 2026-01-26. Section “Director Compensation”. As printed: 136,332. View filing ↗
- Section 08, Kristine Peterson. DEF 14A, filed 2026-01-26. Section “Director Compensation”. As printed: 131,332. View filing ↗
- Section 08, Lesley Russell, MBChB, MRCP. DEF 14A, filed 2026-01-26. Section “Director Compensation”. As printed: 126,332. View filing ↗
- Section 08, Yujiro Hata. DEF 14A, filed 2026-01-26. Section “Director Compensation”. As printed: 123,832. View filing ↗
- Section 08, Jay R. Luly, Ph.D. DEF 14A, filed 2026-01-26. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Brendan Luu 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay Luly 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay Luly 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay Luly 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yat Sun Or 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yat Sun Or 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yat Sun Or 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Rottinghaus 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Rottinghaus 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Rottinghaus 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tara Lynn Kieffer 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tara Lynn Kieffer 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brendan Luu 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tara Lynn Kieffer 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brendan Luu 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Paul Kowalsky 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Paul Kowalsky 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Paul Kowalsky 2026-02-12. Form 4, filed 2026-02-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, CARTER BRUCE L A 2026-03-11. Form 4, filed 2026-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark G. Foletta 2026-03-11. Form 4, filed 2026-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yujiro Hata 2026-03-11. Form 4, filed 2026-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristine Peterson 2026-03-11. Form 4, filed 2026-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lesley Russell 2026-03-11. Form 4, filed 2026-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry C. Vance 2026-03-11. Form 4, filed 2026-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Rottinghaus 2026-08-08. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-03-12. Item 5.07 · say-on-pay result. As reported: 97.22% (votes for as printed: 24,228,898). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-03-17. Item 5.07 · say-on-pay result. As reported: 93.32% (votes for as printed: 14,516,861). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 447,500 + equity 0 + all other 0 = 447,500, summed across the director compensation table rows.
- Travere Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. View filing ↗
- Altimmune, Section 10b CEO total. DEF 14A, filed 2026-03-17. CEO total compensation as printed in Altimmune's own proxy. As printed: 8,026,590. View filing ↗
- Sage Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. View filing ↗
- Nektar Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Nektar Therapeutics's own proxy. As printed: 6,256,954. View filing ↗
- Allogene Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. View filing ↗
- Rigel Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals's own proxy. As printed: 4,658,805. View filing ↗
- Vanda Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals's own proxy. As printed: 3,851,468. View filing ↗
- Lexicon Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Lexicon Pharmaceuticals's own proxy. As printed: 3,553,953. View filing ↗
- Heron Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. View filing ↗
- Enanta Pharmaceuticals Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-01-26. CEO total compensation as printed in Enanta Pharmaceuticals Inc's own proxy. As printed: 2,769,548. View filing ↗
- Karyopharm Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. View filing ↗
- Arcturus Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Arcturus Therapeutics's own proxy. As printed: 1,691,000. View filing ↗
- Inovio Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Inovio Pharmaceuticals's own proxy. As printed: 1,587,155. View filing ↗
- Section 10a, Vanda Pharmaceuticals reciprocity. DEF 14A. Vanda Pharmaceuticals names Enanta Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗